Trials / Terminated
TerminatedNCT00849667
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,100 (actual)
- Sponsor
- Morphotek · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Farletuzumab | Farletuzumab IV infusion. |
| DRUG | Carboplatin | Carboplatin IV infusion. |
| DRUG | Taxane | Taxane (Paclitaxel or Docetaxel) IV infusion. |
| DRUG | Farletuzumab-matched placebo | Farletuzumab-matched placebo IV infusion. |
Timeline
- Start date
- 2009-04-16
- Primary completion
- 2012-12-31
- Completion
- 2013-04-12
- First posted
- 2009-02-24
- Last updated
- 2022-12-30
- Results posted
- 2022-12-30
Locations
375 sites across 30 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Philippines, Poland, Portugal, Russia, Singapore, South Korea, Spain, Switzerland, Taiwan, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00849667. Inclusion in this directory is not an endorsement.